Axial Spondyloarthritis: Beyond TNF Inhibitor Therapy in Ankylosing Spondylitis
Source: Rheumatology in Practice

Module

In this resource, Mazen Elyan, MD, MS, FACR, describes the management of ankylosing spondylitis before, during, and beyond tumor necrosis factor inhibitor therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate clinical guidelines and clinical trial findings into patient treatment at the point of care to improve outcomes for patients with ankylosing spondylitis
  • Apply current guidelines for the use of biologic agents to optimize the care of patients with ankylosing spondylitis
  • Discuss the future directions of novel agents in development and approved agents in clinical trials for the management of ankylosing spondylitis

Topics Covered Include:

  • Introduction
  • Ankylosing Spondylitis Treatment Overview
  • TNF Inhibitors
  • Beyond TNF Inhibitor Therapy
  • Monitoring Disease Activity During Treatment
 

Faculty

  • Mazen Elyan
    MD, MS, FACR

Credit Information

  • Release Date:
    December 15, 2016
  • Expiration Date:
    December 14, 2017
  • Physicians:
    maximum of 0.5 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Mazen Elyan, MD, MS, FACR


Rheumatologist
Department of Rheumatology
Franciscan Physician Network
Indianapolis, Indiana

Mazen Elyan, MD, MS, FACR, has nothing to disclose with regard to commercial interests.
 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has nothing to disclose with regard to commercial interests interests.
 

Heather Stieglitz, PhD


Editorial Contributor

Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.
 

Alyce Kuklinski, NP, RN


General Manager, Virology & Other Therapeutic Specialties

Alyce Kuklinski, NP, RN, has nothing to disclose with regard to commercial interests.
 

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

 

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the medical management of patients with rheumatologic conditions.


Goal

The goal of this activity is to improve the knowledge and competence of physicians and other healthcare providers for the prevention, diagnosis, and treatment of patients with rheumatologic conditions.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate clinical guidelines and clinical trial findings into patient treatment at the point of care to improve outcomes for patients with ankylosing spondylitis
  • Apply current guidelines for the use of biologic agents to optimize the care of patients with ankylosing spondylitis
  • Discuss the future directions of novel agents in development and approved agents in clinical trials for the management of ankylosing spondylitis
 

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Clinical Care Options, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Boston University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Genentech, and Lilly USA, LLC..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2016, through December 14, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • New Developments in Ankylosing Spondylitis from EULAR 2016

    Atul Deodhar MD - 7/15/2016    1 comment / Last Comment: 8/13/2016
    Dr. Atul Deodhar reviews new insights into the pathogenesis of AS and clinical trial updates that may affect your practice.
  • My Take on New ASAS/EULAR Recommendations for Managing Axial Spondyloarthritis

    Atul Deodhar MD - 7/22/2016    
    I describe noteworthy differences between the newly updated ASAS/EULAR recommendations and the ACR/SAA/SPARTAN recommendations.